Raymond James analyst Michael Freeman raised the firm’s price target on NervGen Pharma (NGENF) to C$6 from C$4.50 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGENF:
- NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
- NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
- NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
- NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
- NervGen Pharma Awards Stock Options to Directors and Employees